{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:28:34Z","timestamp":1787596114926,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pntd.0014666","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000}}],"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-kala-azar dermal leishmaniasis (PKDL) is a neglected complication of visceral leishmaniasis (VL) treatment with significant public health implications, particularly in Eastern Africa where it can sustain interepidemic transmission. Despite its importance, no comprehensive synthesis of PKDL burden, risk factors, and treatment outcomes specific to the region exists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This systematic review and meta-analysis followed PRISMA 2020 guidelines and JBI methodology. A comprehensive search was conducted across PubMed\/MEDLINE, Scopus, AJOL, and the Cochrane Library from database inception through May 12, 2026. Studies reporting PKDL incidence, risk factors, or treatment outcomes among VL patients in Eastern Africa were eligible. Random-effects meta-analysis was used to pool cumulative incidence estimates, and heterogeneity was assessed using the I\n                      <jats:sup>2<\/jats:sup>\n                      statistic. For risk factor and treatment outcome studies, a narrative synthesis were performed. Meta-analyses were performed using the meta package in R version 4.5.2 (2025-10-31).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven studies encompassing 4,699 patients from Sudan, Ethiopia, Kenya, and Uganda were included. The pooled cumulative PKDL incidence was 18.2% (95% CI: 4.7%\u201349.7%), with substantial heterogeneity (I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200998.1%). Follow-up duration for PKDL assessment varied across studies, ranging from 6 to 24 months. Significant geographic and temporal variation was observed. Sudan reported the highest pooled incidence (56.7%) in studies conducted during the SSG-monotherapy era (1994\u20132000), compared to Ethiopia (4.6%, 2021) and multi-country cohorts (8.2%, 2022), with more recent supervised treatment data from Sudan and Kenya (2024) showing substantially lower incidence. A temporal decline was noted, from 56.7% pre-2010 to 6.4% post-2010, coinciding with the transition away from sodium stibogluconate monotherapy. Key risk factors included VL treatment regimen, younger age, geographic location, and HIV co-infection. The miltefosine plus paromomycin (MF\u2009+\u2009PM) combination achieved a clinical cure rate of 98.2% in a Phase II trial, outperforming liposomal amphotericin B combinations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PKDL remains a significant post-treatment complication in Eastern Africa, with treatment regimen as the most critical modifiable risk factor. MF\u2009+\u2009PM shows promise as a preferred first-line PKDL therapy. Standardized surveillance and multicountry prospective studies are urgently needed to support regional elimination goals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Registration number<\/jats:title>\n                    <jats:p>CRD420261411634.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pntd.0014666","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:35:21Z","timestamp":1787074521000},"page":"e0014666","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["From visceral to visible: A systematic review and meta-analysis of post-kala-azar dermal leishmaniasis incidence, risk factors, and treatment outcomes in Eastern Africa"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-4328","authenticated-orcid":true,"given":"Eyob Girma","family":"Abera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0054-5911","authenticated-orcid":true,"given":"Surafel Worku","family":"Megersa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kedir Negesso","family":"Tukeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermias Habte","family":"Gebremichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"pntd.0014666.ref001","unstructured":"Organization WH. World Health Organization Leishmaniasis Factsheet. 2023."},{"key":"pntd.0014666.ref002","doi-asserted-by":"crossref","first-page":"1488741","DOI":"10.3389\/fpubh.2024.1488741","article-title":"Prevalence of human visceral leishmaniasis and its risk factors in Eastern Africa: a systematic review and meta-analysis","volume":"12","author":"AK Geto","year":"2024","journal-title":"Front Public Health"},{"issue":"2","key":"pntd.0014666.ref003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"EE Zijlstra","year":"2003","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pntd.0014666.ref004","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/cid\/ciy891","article-title":"Quantifying the infectiousness of post-kala-azar dermal leishmaniasis toward sand flies","volume":"69","author":"D Mondal","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"7","key":"pntd.0014666.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008221","article-title":"Post kala-azar dermal leishmaniasis: a threat to elimination program","volume":"14","author":"MR Gedda","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0014666.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0013952","article-title":"Risk factors for post-kala-azar dermal leishmaniasis (PKDL): challenges in understanding pathophysiology","volume":"20","author":"EE Zijlstra","year":"2026","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0014666.ref007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005877","article-title":"Post-kala-azar dermal leishmaniasis in the Indian subcontinent: A threat to the South-East Asia Region Kala-azar Elimination Programme","volume":"11","author":"EE Zijlstra","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014666.ref008","article-title":"Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in Eastern Africa: a randomized, controlled, multicountry trial","volume":"76","author":"AM Musa","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pntd.0014666.ref009","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40261-016-0481-0","article-title":"Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in Eastern Africa: results from a pharmacovigilance programme","volume":"37","author":"R Kimutai","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"9","key":"pntd.0014666.ref010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163047","article-title":"A comparison of the effectiveness of sodium stibogluconate monotherapy to sodium stibogluconate and paromomycin combination for the treatment of severe post kala azar dermal leishmaniasis in South Sudan - a retrospective cohort study","volume":"11","author":"C Abongomera","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"pntd.0014666.ref011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011780","article-title":"Safety and efficacy of paromomycin\/miltefosine\/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study","volume":"17","author":"BM Younis","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014666.ref012","doi-asserted-by":"crossref","first-page":"101310","DOI":"10.1016\/j.omtm.2024.101310","article-title":"A randomized, double-blind phase 2b trial to evaluate efficacy of ChAd63-KH for treatment of post kala-azar dermal leishmaniasis","volume":"32","author":"BM Younis","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"pntd.0014666.ref013","unstructured":"DNDi. New treatments for PKDL (Eastern Africa). 2026. https:\/\/dndi.org\/research-development\/portfolio\/new-treatments-pkdl-eastern-africa\/"},{"key":"pntd.0014666.ref014","first-page":"1","author":"S Review","year":"2021","journal-title":"Systematic review module 1 introduction to evidence-based healthcare and the systematic session 1 introduction to JBI"},{"key":"pntd.0014666.ref015","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"pntd.0014666.ref016","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JPT Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"6","key":"pntd.0014666.ref017","doi-asserted-by":"crossref","first-page":"826","DOI":"10.4269\/ajtmh.1994.51.826","article-title":"Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis","volume":"51","author":"EE Zijlstra","year":"1994","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"pntd.0014666.ref018","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1365-2133.2000.03603.x","article-title":"Post-kala-azar dermal leishmaniasis in the Sudan: clinical presentation and differential diagnosis","volume":"143","author":"EE Zijlstra","year":"2000","journal-title":"Br J Dermatol"},{"issue":"8","key":"pntd.0014666.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0009713","article-title":"Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg\/kg\/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg\/kg\/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia","volume":"15","author":"A Tamiru","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0014666.ref020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0306067","article-title":"Visceral leishmaniasis follow-up and treatment outcomes in Tiaty East and West sub-counties, Kenya: Cure, relapse, and Post Kala-azar Dermal Leishmaniasis","volume":"19","author":"GC Kennedy","year":"2024","journal-title":"PLoS One"},{"issue":"3","key":"pntd.0014666.ref021","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0035-9203(92)90294-M","article-title":"Post kala-azar dermal leishmaniasis in the Sudan: clinical features, pathology and treatment","volume":"86","author":"AM el Hassan","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"6","key":"pntd.0014666.ref022","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1179\/136485905X514127","article-title":"Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL)","volume":"99","author":"AM Musa","year":"2005","journal-title":"Ann Trop Med Parasitol"},{"key":"pntd.0014666.ref023","author":"WH Organization","year":"2013","journal-title":"Post-kala-azar dermal leishmaniasis: a manual for case management and control: report of a WHO consultative meeting, Kolkata, India, 2\u20133 July 2012"},{"key":"pntd.0014666.ref024","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1756-3305-6-196","article-title":"Report of the post kala-azar dermal leishmaniasis (PKDL) consortium meeting, New Delhi, India, 27\u201329 June 2012","volume":"6","author":"P Desjeux","year":"2013","journal-title":"Parasites Vectors"},{"issue":"4","key":"pntd.0014666.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011635","article-title":"Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: a systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform","volume":"18","author":"S Singh-Phulgenda","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0014666.ref026","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000889","article-title":"Inference of population structure of Leishmania donovani strains isolated from different Ethiopian visceral leishmaniasis endemic areas","volume":"4","author":"T Gelanew","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0014666.ref027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0013144","article-title":"Direct sequencing of Leishmania donovani from patients in Garissa County, Northern Kenya, reveals a newly emerging intra-specific hybrid genotype","volume":"20","author":"VK Omwenga","year":"2026","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0014666.ref028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0030071","article-title":"Y chromosome lineage- and village-specific genes on chromosomes 1p22 and 6q27 control visceral leishmaniasis in Sudan","volume":"3","author":"EN Miller","year":"2007","journal-title":"PLoS Genet"},{"key":"pntd.0014666.ref029","doi-asserted-by":"crossref","first-page":"105474","DOI":"10.1016\/j.ebiom.2024.105474","article-title":"Prediction of visceral leishmaniasis development in a highly exposed HIV cohort in Ethiopia based on Leishmania infection markers: results from the PreLeisH study","volume":"110","author":"J van Griensven","year":"2024","journal-title":"EBioMedicine"},{"issue":"6","key":"pntd.0014666.ref030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002869","article-title":"Visceral Leishmaniasis and HIV coinfection in East Africa","volume":"8","author":"E Diro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0014666.ref031","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1111\/tmi.12603","article-title":"Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan","volume":"20","author":"AM Atia","year":"2015","journal-title":"Trop Med Int Health"},{"issue":"10","key":"pntd.0014666.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000709","article-title":"Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial","volume":"4","author":"A Hailu","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014666.ref033","doi-asserted-by":"crossref","first-page":"108687","DOI":"10.1016\/j.exppara.2023.108687","article-title":"Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL)","volume":"257","author":"G-J Wijnant","year":"2024","journal-title":"Exp Parasitol"},{"issue":"1","key":"pntd.0014666.ref034","first-page":"38","article-title":"Impact of amphotericin-B in the treatment of kala-azar on the incidence of PKDL in Bihar, India","volume":"128","author":"CP Thakur","year":"2008","journal-title":"Indian J Med Res"},{"key":"pntd.0014666.ref035","unstructured":"DNDi. Better, shorter combination treatment for people with visceral leishmaniasis shown to be effective in Eastern Africa. 2022. [cited 2026 Jun 5] https:\/\/dndi.org\/press-releases\/2022\/better-shorter-combination-treatment-for-visceral-leishmaniasis-shown-effective-eastern-africa\/"},{"key":"pntd.0014666.ref036","volume-title":"WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia","author":"WH Organization","year":"2022"},{"key":"pntd.0014666.ref037","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/B978-0-323-40181-4.00296-6","article-title":"Antiparasitic Agents","author":"ET Ryan","year":"2018","journal-title":"Principles and Practice of Pediatric Infectious Diseases"},{"issue":"3","key":"pntd.0014666.ref038","article-title":"Challenges for maintaining post elimination phase of visceral leishmaniasis control programme in India: a field-based study","volume":"18","author":"SK Guha","year":"2024","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0014666.ref039","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13071-016-1292-0","article-title":"Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models","volume":"9","author":"EA Le Rutte","year":"2016","journal-title":"Parasit Vectors"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0014666","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:45:18Z","timestamp":1787593518000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014666"}},"subtitle":[],"editor":[{"given":"Hira L","family":"Nakhasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014666","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}